
Opinion|Videos|April 25, 2025
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
Author(s)Alexandra K. Golant, MD
Alexandra Golant, MD discusses how the availability of topical ruxolitinib data in children as young as age 2 could potentially shift pediatric atopic dermatitis treatment guidelines by providing a non-steroidal alternative with a favorable safety profile.
Advertisement
This news content has been independently developed and is not endorsed by the American Academy of Dermatology.
Video content above is prompted by the following:
- We now have data on topical ruxolitinib down to age 2. Do you think the introduction of topical JAK inhibitors for younger children could shift treatment guidelines for pediatric AD? Why or why not?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Real-World Study Finds Experienced Dermatologists Outperform AI in Skin Cancer Diagnosis
2
New Consensus Defines Remission, Disease Activity in Atopic Dermatitis
3
Beyond Retinol: Evaluating the Stability, Safety, and Gene-Expression Profile of Bakuchiol Ferulate
4
Zasocitinib Shows High Skin Clearance at Hard-to-Treat Psoriasis Sites
5

















